Get started

Grit Biotechnology (China)

Homepage: grit-bio.com
Alternate names: Grit Bio, Grit Biotechnology, Shanghai Grit Biotechnology Co., Ltd., Zhuhai Grit Biotechnology Co., Ltd., Zhuhai Sha Li Biotechnology Co., Ltd.
ROR: 03e4rtx11
OpenAlex ID: I4405267593
Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
2021 · Shuhang Wang, Jingwei Sun, et al. · BMC Medicine · 234
PDF
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer
2023 · Yanbin Liu, Zhenjiang Liu, et al. · British Journal of Cancer · 53
PDF
The Landscape of Cell and Gene Therapies for Solid Tumors
2021 · Shuhang Wang, Fa Sun, et al. · Cancer Cell · 29
PDF
The toxicity of cell therapy: Mechanism, manifestations, and challenges
2020 · Yongjia Jin, Yan Dong, et al. · Journal of Applied Toxicology · 19
Modulation of intracellular kinase signaling to improve TIL stemness and function for adoptive cell therapy
2022 · Hao Feng, Ling Qiu, et al. · Cancer Medicine · 16
Precision In Vivo CAR-T generation via CLAMP-enabled mRNA delivery: Toward scalable and translatable cell therapy
2025 · Jingwei Sun, Xi Zhu, et al. · Blood · 10
PDF
A first-in-human study of CRISPR/Cas9-engineered tumor infiltrating lymphocytes (TILs) product GT316 as monotherapy in advanced solid tumors.
2024 · Jing Guo, Wei Huang, et al. · Journal of Clinical Oncology · 6
Engineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy
2025 · Xiao Chen, Dunfang Liu, et al. · Advanced Science · 5
Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.
2023 · Yarong Liu, Weijia Fang, et al. · Journal of Clinical Oncology · 5
High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness
2025 · Jingwei Sun, Ke Liu, et al. · Molecular Therapy · 4
GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
2025 · Haifeng Qin, Yongsheng Wang, et al. · Journal of Clinical Oncology · 3
Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.
2024 · Zhengxiang Han, Weijia Fang, et al. · Journal of Clinical Oncology · 3
First-in-human study of in vivo CAR-T therapy GT801 in adults with relapsed or refractory CD19-positive B-cell hematologic malignancies.
2026 · Yarong Liu, Li Wang, et al. · Journal of Clinical Oncology · 2
Assessing the safety and efficacy of GT201: A first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.
2025 · Pin Wang, Jing Yu, et al. · Journal of Clinical Oncology · 2
PDF
Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors.
2024 · Haifeng Qin, Yongsheng Wang, et al. · Journal of Clinical Oncology · 2
Abstract 5581: A genetically modified tumor-infiltrating lymphocytes product (GT202) exhibits enhanced persistence and anti-tumor efficacy against solid tumor in vivo
2022 · Jingwei Sun, Jiahui Jin, et al. · Cancer Research · 2
Abstract 148: In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions.
2026 · Jingwei Sun, Xi Zhu, et al. · Cancer Research · 1
Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical mapping study in a neuroendocrine cancer patient
2026 · Xinyu Gao, Zhenjiang Liu, et al. · Cellular Oncology · 1
PDF
559 Trial in progress: first in human study of GT601, a next-generation neoantigen cancer vaccine for hepatocellular carcinoma
2025 · Pin Wang, Liqing Ma, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma.
2025 · Matthias Schroff, Bo Liu, et al. · Journal of Clinical Oncology · 1
Evaluating the safety and efficacy of CRISPR/AaCas12b Max -modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors.
2025 · Pin Wang, Haifeng Qin, et al. · Journal of Clinical Oncology · 1
Abstract 3192: GT316: a next-generation TIL therapy identified through genome-wide CRISPR screening with promising efficacy in advanced solid tumors
2025 · Jingwei Sun, Yao Sheng, et al. · Cancer Research · 1
T cell receptor repertoire characteristics and therapeutic potential of tumor infiltrating lymphocytes (TILs) derived from metastatic lymph node in cervical cancer
2024 · Xuan Zhao, Zhenjiang Liu, et al. · Molecular Biomedicine · 1
PDF
Abstract 29: A genetically modified tumor-infiltrating lymphocytes product (GT216) enhanced anti-tumor efficacy against solid tumor by fine-tuning multiple negative immune regulators
2024 · Jingwei Sun, Yiyang Tan, et al. · Cancer Research · 1
Abstract 4062: The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy
2023 · Yarong Liu, Jingwei Sun, et al. · Cancer Research · 1
Works count: 54
Citation count: 1,595
Year
Topic
Type